Our group analyzed the association between Ob-R, TILs, and pCR in a group of 87 patients with breast cancer (luminal, triple-negative, and HER2 subtypes by immunohistochemistry) treated with neoadjuvant chemotherapy. This evidence concerns the gene ERBB2 and breast cancer.